CGRP Education & Research Forum https://validator.w3.org/feed/docs/rss2.html Atogepant superior to topiramate in Phase 3 TEMPLE study Welcome to CGRP Forum A multicentre, randomised, double blind, placebo controlled, parallel-group study comparing the efficacy, safety and tolerability of subcutaneous administration of fremanezumab versus placebo for the preventive treatment of episodic migraine in paediatric patients 6-17 years of age (SPACE, NCT04458857) Welcome to CGRP Forum Top-line PROCEED data support anti-PACAP mAb in migraine prevention Rimegepant improves migraine in adolescents CGRP in the Journals Welcome to CGRP Forum Combining onabotulinumtoxinA and anti-CGRP therapies in migraine prevention US prescription claims data highlight anti-CGRP therapy switching rates Welcome to CGRP Forum ECLIPSE data support atogepant for acute migraine treatment SYNERGY real world data show benefits of combining atogepant with onabotulinumtoxinA 2025: Spotlight on advances in migraine care False non-responders can benefit from CGRP mAbs given time AHS proposes annual migraine screening for women Bridging CGRP mAbs with gepants: An innovative approach to address the wearing-off phenomenon Governance Assessing the safety and efficacy of utilizing CGRP mAb fremanezumab in chronic migraine patients currently on monotherapy onabotulinumtoxinA (COACT) (NCT05724771) Meetings Norwegian registry reports effects of CGRP mAb exposure during pregnancy Redefining a migraine day to reduce variability Should patients switch to a CGRP mAb or a gepant? UNION study confirms ubrogepant efficacy with CGRP mAbs CGRP mAb experience at a major UK centre Study of oral atogepant tablets to assess safety and efficacy in adult participants with migraine (ATO ACUTE/ECLIPSE, NCT06241313) Phase 3 study of oral atogepant to assess adverse events and change in disease activity in adult participants with menstrual migraine (ATO MM, NCT06806293) An observational study to assess ubrogepant tablets and atogepant tablets to treat migraine in adult participants (COBRA, NCT05827887) Adverse events when ubrogepant or atogepant are taken during pregnancy (EMPRESS, NCT05158894) Study of oral ubrogepant to assess adverse events and change in disease activity in adult participants with menstrual migraine (UBRO MM, NCT06417775) CGRP mAbs do not significantly change inflammatory mediator levels Breaking down access barriers to newer preventive therapies Best responders to CGRP mAbs need treatment persistence A Phase 3, multicentre, randomised, double-blind, placebo-group study to evaluate the efficacy, safety and tolerability of atogepant for the prevention of chronic migraine (PROGRESS) (NCT03855137) Phase 4 study to assess adverse events when ubrogepant tablets are used with atogepant tablets to treat adults with migraine (TANDEM, NCT05264129) Phase 3 study of oral atogepant tablets to assess adverse events and change in disease activity to prevent migraine in participants aged 12 to 17 Years (NCT06810505) Phase 3 comparative study of oral atogepant versus oral topiramate to assess adverse events in adults with migraine (ATO-TOPIRAMATE/TEMPLE, NCT05748483) A Phase 3, multicentre, open-label 40-week extension study to evaluate the long-term safety and tolerability of oral atogepant for the prevention of migraine in participants with episodic migraine (NCT03939312) Atogepant for migraine prophylaxis in patients who failed previous oral prophylactic treatments (ELEVATE) (NCT04740827) Long term safety study of zavegepant (BHV-3500) for the acute treatment of migraine (NCT04408794) Oral ubrogepant in the acute treatment of migraine when administered during the prodrome (PRODROME) (NCT04492020) Ubrogepant efficacy and safety in the treatment of acute migraine in patients currently treated with CGRP monoclonal antibodies (UNION) (NCT05503082) A randomized, parallel-group, single-attack, open-label study to evaluate the efficacy of almotriptan and ubrogepant for the acute treatment of migraine (ATOM) (NCT05214001) A Phase 3 trial to evaluate the efficacy, safety, tolerability, and pharmacokinetics of oral ubrogepant in the acute treatment of migraine with or without aura in children and adolescents (ages 6-17) (NCT05125302) Atogepant for migraine prophylaxis in patients who failed previous oral prophylactic treatments (ELEVATE) (NCT04740827) A Phase 3 Multicenter 24-Week Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of atogepant When Added to OnabotulinumtoxinA (BOTOX) for the Preventive Treatment of Chronic Migraine (NCT05216263) A Phase 1b, two-part, open-label, fixed-sequence, safety, tolerability and drug-drug interaction study between single dose erenumab or galcanezumab and multiple dose ubrogepant in participants with migraine (NCT04179474) A Phase 3, multicenter, 12-week, double blind, placebo-controlled study to evaluate the safety and efficacy of atogepant for the preventive treatment of episodic migraine in pediatric subjects aged 6-17 years of age (NCT05711394) Comparative effectiveness of migraine preventive medications (APT, NCT06972056) Real world data show sustained CGRP mAb benefits at three years